aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
Company profile
Ticker
AUPH
Exchange
Website
CEO
Peter Greenleaf
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aurinia Pharma U.S., Inc. • Aurinia Pharma Limited ...
AUPH stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
29 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
15 Feb 24
8-K
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
5 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
2 Nov 23
8-K
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
21 Sep 23
8-K
Dr. Daniel G. Billen appointed Chair of the Board of Directors
21 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
3 Aug 23
Transcripts
AUPH
Earnings call transcript
2023 Q4
15 Feb 24
AUPH
Earnings call transcript
2023 Q2
3 Aug 23
AUPH
Earnings call transcript
2023 Q1
4 May 23
AUPH
Earnings call transcript
2022 Q4
28 Feb 23
AUPH
Earnings call transcript
2022 Q3
3 Nov 22
AUPH
Earnings call transcript
2022 Q2
4 Aug 22
AUPH
Earnings call transcript
2022 Q1
10 May 22
AUPH
Earnings call transcript
2021 Q4
28 Feb 22
AUPH
Earnings call transcript
2021 Q3
3 Nov 21
AUPH
Earnings call transcript
2021 Q2
6 Aug 21
Latest ownership filings
SC 13D/A
ILJIN SNT Co., Ltd.
20 Mar 24
4
Peter Greenleaf
7 Mar 24
4
Joseph M Miller
7 Mar 24
4
Matthew Maxwell Donley
7 Mar 24
4
Scott Michael Habig
7 Mar 24
4
Stephen P. Robertson
7 Mar 24
4
Volker Knappertz
29 Feb 24
4
Volker Knappertz
22 Feb 24
4
Scott Michael Habig
22 Feb 24
4
Matthew Maxwell Donley
22 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm |
Cash burn (monthly) | 11.77 mm | 3.30 mm | 5.42 mm | 7.51 mm | 4.43 mm | 3.11 mm |
Cash used (since last report) | 70.21 mm | 19.71 mm | 32.34 mm | 44.80 mm | 26.40 mm | 18.55 mm |
Cash remaining | -23.82 mm | 26.68 mm | 14.06 mm | 1.60 mm | 20.00 mm | 27.84 mm |
Runway (months of cash) | -2.0 | 8.1 | 2.6 | 0.2 | 4.5 | 9.0 |
Institutional ownership, Q3 2023
38.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 197 |
Opened positions | 24 |
Closed positions | 24 |
Increased positions | 67 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 384.06 bn |
Total shares | 56.29 mm |
Total puts | 1.10 mm |
Total calls | 1.97 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.41 mm | $65.36 bn |
ILJIN SNT | 6.06 mm | $0.00 |
Armistice Capital | 6.05 mm | $46.99 bn |
NEA Management | 3.97 mm | $30.85 bn |
STT State Street | 2.60 mm | $20.20 bn |
Nuveen Asset Management | 2.35 mm | $18.28 bn |
Geode Capital Management | 1.49 mm | $11.56 bn |
Vanguard | 1.48 mm | $11.53 bn |
GS Goldman Sachs | 1.47 mm | $11.44 bn |
MS Morgan Stanley | 1.42 mm | $11.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Greenleaf Peter | Common Stock | Sell | Dispose S | No | No | 5.6 | 126,981 | 711.09 k | 1,522,114 |
6 Mar 24 | Miller Joseph M | Common Stock | Sell | Dispose S | No | No | 5.6 | 34,811 | 194.94 k | 495,928 |
6 Mar 24 | Matthew Maxwell Donley | Common Stock | Sell | Dispose S | No | No | 5.51 | 40,665 | 224.06 k | 584,072 |
6 Mar 24 | Scott Michael Habig | Common Stock | Sell | Dispose S | No | No | 5.6 | 17,777 | 99.55 k | 474,587 |
6 Mar 24 | Stephen P. Robertson | Common Stock | Sell | Dispose S | No | No | 5.6 | 57,745 | 323.37 k | 443,824 |
News
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
1 Mar 24
Cantor Fitzgerald Maintains Overweight on Aurinia Pharmaceuticals, Lowers Price Target to $10
23 Feb 24
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
22 Feb 24
HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Lowers Price Target to $13
22 Feb 24
RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Lowers Price Target to $8
16 Feb 24
Press releases
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
29 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
15 Feb 24
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
5 Feb 24
Kane Biotech Announces Special Meeting of Shareholders
18 Jan 24
Thinking about buying stock in C3.ai, Altimmune, Altria Group, Fusion Pharmaceuticals, or Aurinia Pharmaceuticals?
5 Jan 24